Stockscreener 앱 받기
192.86
0.79%
-1.36
전일 마감가:
$194.22
열려 있는:
$190.33
하루 거래량:
1.18M
Relative Volume:
0.22
시가총액:
$298.99B
수익:
$58.80B
순이익/손실:
$10.24B
주가수익비율:
58.82
EPS:
3.2788
순현금흐름:
$8.98B
1주 성능:
-5.42%
1개월 성능:
+2.48%
6개월 성능:
+137.23%
1년 성능:
+148.62%
1일 변동 폭
$189.35
$193.93
1주일 범위
$189.35
$203.29
52주 변동 폭
$61.24
$212.71
아스트라제네카 ADR Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
192.80 | 301.19B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
LLY
Lilly Eli Co
|
997.44 | 884.36B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
241.91 | 579.34B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
225.52 | 406.87B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
161.29 | 305.53B | 54.72B | 14.02B | 15.32B | 7.1855 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 개시 | Citigroup | Buy |
| 2025-10-27 | 재개 | Jefferies | Buy |
| 2025-10-16 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
AstraZeneca (AZN) Achieves Priority Review for Enhertu in Breast Cancer Treatment - GuruFocus
AstraZeneca, Daiichi Sankyo Wins Priority Review for Enhertu for Breast Cancer - marketscreener.com
AstraZeneca (AZN) and Other Drugmakers Watch as Key FDA Official Resigns - GuruFocus
AstraZeneca’s AZD5004 Formulation Trial: Early Data Point for Long-Term Pipeline Value - TipRanks
AstraZeneca CEO Pascal Soriot receives vested shares under performance plan - Investing.com UK
AstraZeneca executives receive vested shares under deferred bonus plan - Investing.com
AstraZeneca (AZN) CEO awarded 101,495 shares on AZPSP vesting - Stock Titan
AstraZeneca awards share grants to CEO and CFO under company incentive plans - Investing.com UK
AstraZeneca (NYSE: AZN) awards deferred bonus shares to leaders - Stock Titan
Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial - Proactive financial news
Longfellow Investment Management Co. LLC Makes New Investment in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Stock Holdings Raised by Orion Porfolio Solutions LLC - MarketBeat
AstraZeneca Executives Receive Vested Deferred Share Awards - TipRanks
AstraZeneca Grants Long-Term Share Awards to CEO and CFO - TipRanks
The Zacks Analyst Blog Highlights Exxon Mobil, Palantir, AstraZeneca, Gencor Industries and Hour Loop - Yahoo Finance Singapore
243,177 Shares in AstraZeneca PLC $AZN Purchased by Foresight Global Investors Inc. - MarketBeat
Top Analyst Reports for Exxon Mobil, Palantir & AstraZeneca - Yahoo Finance
GLP-1 Receptor Agonist (Trulicity, Wegovy, Ozempic, Mounjaro) Market Trends Analysis Report 2026 - GlobeNewswire Inc.
HAP Trading LLC Sells 7,267 Shares of AstraZeneca PLC $AZN - MarketBeat
Mengis Capital Management Inc. Boosts Stock Position in AstraZeneca PLC $AZN - MarketBeat
Dimensional Fund Advisors LP Raises Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Position Lessened by Teachers Retirement System of The State of Kentucky - MarketBeat
AstraZeneca (AZN) Strengthens Clinical Portfolio and Expands Inv - GuruFocus
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
CI Investments Inc. Has $18.33 Million Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca’s New LDL-C Drug AZD0780 Enters Human Testing: What Investors Should Watch - TipRanks
AstraZeneca (AZN) adds three fixed-rate US dollar note issues out to 2036 - Stock Titan
AstraZeneca PLC (AZN) Investor Outlook: Evaluating the Healthcare Giant Amidst a -21.01% Potential Downside - DirectorsTalk Interviews
Morqan Stanley Raises Astrazeneca Price Target to $219 From $109, Overweight Rating Kept - marketscreener.com
AstraZeneca reports total voting rights of over 1.55 billion shares - Investing.com
AstraZeneca (LSE/STO/NYSE: AZN) details 1.55B voting rights - Stock Titan
Fisher Asset Management LLC Acquires 466,745 Shares of AstraZeneca PLC $AZN - MarketBeat
ASTRAZENECA : JP Morgan maintains a Buy rating - marketscreener.com
Rafferty Asset Management LLC Sells 7,892 Shares of AstraZeneca PLC $AZN - MarketBeat
Becker Capital Management Inc. Decreases Position in AstraZeneca PLC $AZN - MarketBeat
Antibiotics Market - GlobeNewswire Inc.
AstraZeneca Says Breast Cancer Treatment Granted US FDA Priority Review - marketscreener.com
American Century Companies Inc. Has $167.79 Million Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC (AZN.L) Stock Report: Analyzing a Healthcare Powerhouse with a $241 Billion Market Cap - DirectorsTalk Interviews
AstraZeneca PLC (NASDAQ:AZN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
AstraZeneca PLC $AZN Shares Bought by US Bancorp DE - MarketBeat
Harvest Portfolios Group Inc. Sells 20,219 Shares of AstraZeneca PLC $AZN - MarketBeat
AlphaCore Capital LLC Increases Stock Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Acquired by TD Asset Management Inc - MarketBeat
Erste Asset Management GmbH Sells 29,313 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange - FinancialContent
Thornburg Investment Management Inc. Sells 24,703 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca has 'sector leading replacement power' to cope with 2030 patent cliff - Yahoo Finance UK
AstraZeneca (AZN) prices $2bn in new fixed-rate global bond tranches - Stock Titan
AstraZeneca prices $2 bln bond offering - marketscreener.com
Primecap Management Co. CA Sells 1,342,120 Shares of AstraZeneca PLC $AZN - MarketBeat
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.68%
0.15%
자본화:
|
볼륨(24시간):